Role of Adjuvant Treatment in Resected Adult Extremity Soft Tissue Sarcoma

Background:Soft tissue sarcomas (STS) are a rare and heterogeneous group of tumors, representing less than 1% of all adult malignancies. Objective: This study aimed to assess long-term outcomes of the adjuvant treatment in resected extremity soft tissue sarcoma patients including overall survival, recurrence free survival and local control. Patients and Methods: This retrospective analytical study based on hospital records of seventy-one patients with resected extremities soft tissue sarcoma who presented to Clinical Oncology and Nuclear Medicine Department, Mansoura University Hospitals, Egypt between January 1 st 2012 to December 31st 2017. Results: Most of the patients underwent upfront surgery (N: 64, 90.1%). Half of them, surgery was enough and didn’t receive any adjuvant treatments (N: 35, 49.3%), while the other half received adjuvant treatment either radiotherapy (N: 25, 35.2%), chemotherapy (N: 6, 8.5%), or both (N: 5, 7%). Only seven patients received neoadjuvant treatments (N: 7, 9.9%). The overall survival (OAS) mean in our study was 60.71 ± 26.82 months while 5-years OAS was 69 %. As regards disease free survival (DFS), mean was 48.57 ± 32.16 months and the 2-years DFS was 73.2 %. Metastasis rate was 15.5%. Disease recurrence rate was 23.9%. Conclusion: Grade of differentiation, necrosis, tumor size, adjuvant treatment, and occurrence of metastasis were the most independent prognostic factors of OAS of extremities STS, while grade of differentiation and tumor size were the most independent DFS prognostic factors.